23andMe CEO plans to take company private

Company head Anne Wojcicki is considering buying all outstanding shares of the DNA testing firm, which has seen its stock slump in recent years.

By Elise Reuter • April 18, 2024

Stelara biosimilar from Alvotech, Teva approved by FDA

The companies plan to launch their copycat version of the blockbuster immune disease drug early next year, per a legal settlement with J&J.

By Kristin Jensen • April 17, 2024

Explore the Trendline➔

Pharma, new drugs and market strategy

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Roche reports survival data for new dual-acting lymphoma drug

The results could give Roche’s Columvi an edge over a rival medicine from AbbVie and Genmab, while Regeneron awaits an approval of its own therapy.

By Jonathan Gardner • April 15, 2024

European regulator concludes no suicide link to obesity drugs

The decision clears a concern hanging over GLP-1 medicines like Ozempic since reports of suicidal ideation and self-harm among people taking the drugs surfaced in July.

By Jonathan Gardner • April 12, 2024

US sues Regeneron, alleging false price reporting on Eylea

The lawsuit claims the drugmaker didn’t disclose reimbursement to drug distributors for credit card fees, artificially inflating the reported price of the blockbuster eye drug.

By Kristin Jensen • April 11, 2024

FDA rejects Regeneron lymphoma drug, setting back company’s oncology push

The agency wants Regeneron to make more progress with a confirmatory trial before clearing odronextamab, a “bispecific” antibody being developed for multiple blood cancers. 

By Jonathan Gardner • March 25, 2024

Give HCPs a proactive way to reach your field team: Add inbound

HCPs today want inbound channels for help when they need it. See how you can meet their preferences.

By Paul Shawah, Executive Vice President of Strategy, Veeva • March 18, 2024

BIO changes stance, backs bill to limit China’s role in US biotech

Pressed by lawmakers, the lobbying group is also “taking steps” to end its relationship with WuXi-AppTec, a major contract manufacturer to the biopharmaceutical industry.

By Jonathan Gardner • March 14, 2024

After surprise trial failure, ALS doctors brace for one less treatment option

Physicians have been preparing for tough conversations with patients on Amylyx's drug since negative confirmatory trial results in March.

By Jacob Bell • Updated April 4, 2024

Novavax agrees to pay Gavi in settlement over COVID vaccine contract

Under the deal’s terms, Novavax will pay the vaccine alliance up to $475 million over five years.

By Kristin Jensen • Feb. 22, 2024

Ipsen drug approved by FDA for early pancreatic cancer

The clearance of Onivyde for first-line pancreatic adenocarcinoma triggers a $225 million payment to Merrimack, from whom Ipsen bought the drug.

By Ned Pagliarulo • Feb. 14, 2024

Biogen has a fuzzy line of sight on prized Alzheimer’s drug

CEO Chris Viehbacher said there are about 3,800 U.S. patients on a registry for Leqembi. But Biogen doesn’t have all the details, as development partner Eisai is leading commercial efforts.

By Jacob Bell • Feb. 13, 2024

Chart a course for sustainable growth

Explore how companies are optimizing efficiency, enhancing customer experiences and embracing AI.

Feb. 12, 2024

Eisai falls behind on Leqembi patient goal

The Alzheimer’s drug was administered to a total of 2,000 U.S. patients as of Jan. 26, signaling to analysts that an earlier goal of 10,000 may take longer than expected to hit.

By Jacob Bell • Feb. 6, 2024

Biogen quits Aduhelm, handing back rights to original developer

The decision to discontinue the controversial drug closes a tumultuous three-year saga that brought significant upheaval to the company.

By Jacob Bell • Jan. 31, 2024

FDA orders new cancer warnings for CAR-T therapies

The agency later modified its warning for Gilead's Tecartus, tweaking the label's language to reflect the fact that none of T cell malignancies in question had occurred in Tecartus-treated patients.

By Jonathan Gardner • Updated Jan. 24, 2024

Biogen CEO sees progress in launch of Alzheimer’s drug Leqembi

At the J.P. Morgan Healthcare Conference Monday, company head Chris Viehbacher said insurance reimbursement is now ‘not an issue’ for treatment.

By Jacob Bell • Jan. 8, 2024

Lilly launches online service for home delivery of weight loss drug

The new program, dubbed LillyDirect, will help patients connect with telehealth providers and deliver medicines like the company’s obesity drug Zepbound.

By Ned Pagliarulo • Jan. 4, 2024

Profitable growth is on the horizon

A return to profitable growth is on the horizon—organizations that take advantage of the following key trends can thrive in 2024 and beyond.

Dec. 11, 2023

CVS overhauls how its retail pharmacies charge for prescription drugs

Under the new model, CVS’ pharmacy network will price drugs based on the amount the company paid for them, plus a defined markup and additional pharmacist fee.

By Rebecca Pifer • Dec. 5, 2023

European regulators want to know more about the risks of GLP-1 drugs

The EMA's safety committee has more questions for makers of the in-demand therapies as it reviews whether the drugs are linked to the risk of suicidal thoughts. 

By Jacob Bell • Dec. 1, 2023

Cigna, Humana in talks to merge: WSJ

The merger would have major effects for the makeup of the U.S. health insurance industry, and would almost certainly face a regulatory challenge.

By Rebecca Pifer • Nov. 29, 2023

Medtronic CEO downplays impact of obesity drugs on procedures, devices

Surging demand for GLP-1 agonists has put medtech firms like Medtronic under pressure, even as they argue the hit to their businesses will be minimal.

By Ricky Zipp • Nov. 21, 2023

Bristol Myers faces FDA delay on cancer cell therapy decision

The regulator plans to convene an advisory panel to discuss an expanded indication for Abecma, presenting another hurdle for Bristol Myers and partner 2seventy bio.

By Ned Pagliarulo • Nov. 20, 2023

New AMA policies target GLP-1 coverage, corporate medicine

The lobbying group urged broader health insurance coverage for treating obesity, including with GLP-1 agonists like Wegovy.

By Susanna Vogel • Nov. 14, 2023